Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs

Biohaven Ltd. (NYSE:BHVN - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for Biohaven in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($6.90) per share for the year, down from their prior forecast of ($6.05). The consensus estimate for Biohaven's current full-year earnings is ($8.85) per share. Leerink Partnrs also issued estimates for Biohaven's FY2027 earnings at ($3.50) EPS and FY2028 earnings at ($1.65) EPS.

Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.03).

A number of other equities research analysts have also recently issued reports on BHVN. TD Cowen lifted their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a "buy" rating and issued a $59.00 price target on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price objective (up from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $63.00.

Biohaven Stock Up 4.2 %

Shares of NYSE:BHVN traded up $1.59 during trading on Friday, reaching $39.30. 381,334 shares of the company's stock traded hands, compared to its average volume of 910,358. The firm has a market cap of $3.97 billion, a PE ratio of -4.20 and a beta of 1.28. Biohaven has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The company has a 50-day simple moving average of $39.50 and a 200-day simple moving average of $42.59.

Institutional Investors Weigh In On Biohaven

A number of institutional investors have recently modified their holdings of the company. Stifel Financial Corp increased its stake in Biohaven by 0.4% during the third quarter. Stifel Financial Corp now owns 6,509,261 shares of the company's stock worth $325,268,000 after purchasing an additional 28,684 shares during the period. Janus Henderson Group PLC lifted its holdings in Biohaven by 5.6% during the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company's stock worth $311,142,000 after buying an additional 328,099 shares in the last quarter. Geode Capital Management LLC boosted its position in Biohaven by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company's stock valued at $85,696,000 after buying an additional 44,174 shares during the period. Point72 Asset Management L.P. grew its stake in shares of Biohaven by 745.9% in the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock worth $74,969,000 after acquiring an additional 1,322,922 shares in the last quarter. Finally, ARS Investment Partners LLC increased its position in shares of Biohaven by 1.0% during the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after acquiring an additional 10,473 shares during the period. 88.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Biohaven

In other news, Director John W. Childs bought 29,000 shares of the business's stock in a transaction on Monday, December 30th. The shares were bought at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the transaction, the director now directly owns 2,368,741 shares in the company, valued at $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 16.00% of the stock is currently owned by insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.